Effectiveness of IG-IMRT for Locally Advanced Cervix Cancer on NRG Trial CVM-1421
NRG 试验 CVM-1421 中 IG-IMRT 对局部晚期宫颈癌的有效性
基本信息
- 批准号:9104120
- 负责人:
- 金额:$ 25.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-02 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AmericanAnteriorBone MarrowBoxingCancer EtiologyCancer PatientCessation of lifeCisplatinClinical TrialsDNA Synthesis InhibitorsDataDiagnosisDiseaseDoseEffectivenessFailureFundingFutureGenitourinary systemGoalsGynecologicHealthIntensity-Modulated RadiotherapyInternationalIntestinesLateralMachine LearningMalignant NeoplasmsMalignant neoplasm of cervix uteriMaximum Tolerated DoseModelingNormal tissue morphologyOrganPatientsPelvisPopulationProgression-Free SurvivalsProtocols documentationQuality of lifeRadiationRadiation therapyRadiation-Sensitizing AgentsRandomizedRegimenResearchResearch PersonnelRibonucleotide Reductase InhibitorSecondary toShapesStagingTechniquesTestingTherapeuticTissuesToxic effectTreatment outcomeTriapineVaccinationchemoradiationchemotherapycomparative effectivenesscontrast imagingdesigngastrointestinalgemcitabineimage guidedimprovedimproved outcomeinterestknowledge basenew technologynoveloncologyphase I trialphase II trialradiation effectrandomized trialscreeningstandard of caretooltreatment planningtumor
项目摘要
DESCRIPTION (provided by applicant): Cervical cancer is among the leading causes of cancer death worldwide. Patients often have poor access to screening and vaccination, and present in advanced stages, for which chemoradiotherapy (chemoRT) is the standard of care. This treatment is limited, however, by high rates of failure and toxicity. Although intensifying chemotherapy can improve tumor control and survival, toxicity is often unacceptably high. Strategies to reduce toxicity while increasing efficacy of chemoRT are therefore needed. Standard pelvic RT techniques encompass large volumes of normal tissue. In contrast, image-guided intensity-modulated RT (IG-IMRT) is a modern technique that maximizes target dose and minimizes normal tissue dose. Multiple studies have found that IG-IMRT can significantly reduce organ dose and reduce toxicity compared to standard RT. These studies support the hypothesis that IG-IMRT can permit delivery of more intensive chemotherapy. For example, gemcitabine, a potent radiosensitizer, has been found to improve survival for cervical cancer patients in randomized trials (Dueñas-Gonzalez et al.). However, the toxicity when delivered with standard RT is extreme (>80% grade 3-4 toxicity). Therefore, this regimen has not replaced cisplatin alone as the standard of care. In contrast, our research group has found that the maximum tolerated dose of gemcitabine was increased when given with IG-IMRT. A large international multi-institutional trial has also found lower rates of toxicity with IG-IMRT compare to standard chemoRT. These findings support the hypothesis that IG-IMRT, by reducing bowel and bone marrow dose, could permit delivery of more effective concurrent chemotherapy. If confirmed, this would have significant implications for many pelvic malignancies. However, this hypothesis has not been tested in a randomized trial. CVM-1421 is an emerging NCI-funded randomized phase II trial within the NRG Oncology Cooperative Group that will test the hypothesis that adding concurrent triapine, a ribonucleotide reductase inhibitor, to concurrent cisplatin and RT can improve outcomes in patients with locoregionally advanced cervix cancer undergoing definitive chemoradiation. This trial presents a unique opportunity to study the effects of IG- IMRT on normal tissue toxicity, as it will be the first cooperative group trial to permit IG-IMRT in this population. This trial also presents an opportunity to study ways to improve IG-IMRT quality, as there has been considerable controversy in how to optimally design IG-IMRT plans, due to their increased complexity. The goal of our research is to study the effect of IG-IMRT on toxicity, quality of life, and treatment outcomes, under varying intensities of chemotherapy. We will also implement a novel technique called knowledge-based planning (KBP) in order to improve plan quality and achieve optimal IG-IMRT dose distributions. This research could help establish IG-IMRT as a new standard of care for pelvic malignancies, and will lay groundwork for future studies testing novel technologies in clinical trial settings.
描述(申请人提供):宫颈癌是全球癌症死亡的主要原因之一。患者往往很难获得筛查和疫苗接种,并处于晚期,而放化疗是治疗的标准。然而,这种治疗受到高失败率和毒性的限制。虽然加强化疗可以改善肿瘤控制和生存率,但毒性往往高得令人无法接受。因此,在提高化疗疗效的同时降低毒性的策略是必要的。标准的盆腔RT技术包括大量的正常组织。相比之下,图像引导调强放射治疗(IG-IMRT)是一种最大限度地增加目标剂量和最小化正常组织剂量的现代技术。多项研究发现,与标准放疗相比,IG-IMRT可以显著减少器官剂量,减少毒性。这些研究支持这样的假设,即IG-IMRT可以提供更密集的化疗。例如,在随机试验中发现吉西他滨是一种有效的放射增敏剂,可以提高宫颈癌患者的存活率(Dueñas-Gonzalez等人)。然而,当使用标准RT时,毒性是极端的(>;80%3-4级毒性)。因此,这种方案并没有单独取代顺铂作为治疗的标准。相反,我们的研究小组发现,使用IG-IMRT时,吉西他滨的最大耐受量增加。一项大型的国际多机构试验也发现,与标准的化疗RT相比,IG-IMRT的毒副作用更低。这些发现支持这样的假设,即IG-IMRT通过减少肠道和骨髓剂量,可以提供更有效的同步化疗。如果得到证实,这将对许多盆腔恶性肿瘤产生重大影响。然而,这一假设尚未在随机试验中得到验证。CVM-1421是NRG肿瘤学合作小组内由NCI资助的一项新的II期随机试验,该试验将测试这样一种假设,即在同时进行顺铂和RT的同时添加核糖核苷酸还原酶抑制剂Triapine可以改善正在接受明确化疗的局部区域晚期宫颈癌患者的预后。这项试验提供了一个独特的机会来研究IG-IMRT对正常组织毒性的影响,因为这将是第一个允许IG-IMRT在这一人群中使用的合作小组试验。这项试验也提供了一个研究如何提高IG-IMRT质量的机会,因为由于IG-IMRT计划的复杂性增加,如何优化设计IG-IMRT计划一直存在相当大的争议。我们研究的目的是研究不同化疗强度下IG-IMRT对毒性、生活质量和治疗结果的影响。我们还将实施一种名为基于知识的计划(KBP)的新技术,以提高计划质量并实现最佳的IG-IMRT剂量分布。这项研究可能有助于建立IG-IMRT作为盆腔恶性肿瘤护理的新标准,并将为未来在临床试验环境中测试新技术的研究奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Loren K. Mell其他文献
Optimized Atlas-Based Auto-Segmentation of Bony Structures from Whole-Body Computed Tomography
- DOI:
10.1016/j.prro.2023.03.013 - 发表时间:
2023-09-01 - 期刊:
- 影响因子:
- 作者:
Lei Gao;Tahir I. Yusufaly;Casey W. Williamson;Loren K. Mell - 通讯作者:
Loren K. Mell
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504
纳武利尤单抗联合放化疗治疗中高危局部晚期头颈鳞状细胞癌平台的安全性:RTOG 基金会 3504
- DOI:
10.1016/j.ijrobp.2022.10.008 - 发表时间:
2023-03-15 - 期刊:
- 影响因子:6.500
- 作者:
Maura L. Gillison;Robert L. Ferris;Jonathan Harris;A. Dimitrios Colevas;Loren K. Mell;Christina Kong;Richard C. Jordan;Kevin L. Moore;Minh-Tam Truong;Claudia Kirsch;Arnab Chakravarti;Dukagjin M. Blakaj;David A. Clump;James P. Ohr;John F. Deeken;Michael F. Gensheimer;Nabil F. Saba;Jennifer A. Dorth;David I. Rosenthal;Rom S. Leidner;Quynh Thu Le - 通讯作者:
Quynh Thu Le
Redefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative Risk
基于相对风险重新定义局部晚期 P16+口咽癌减毒治疗的候选者
- DOI:
10.1016/j.ijrobp.2024.09.035 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:6.500
- 作者:
Ryan T. Morse;Tyler J. Nelson;Hannah C. Liu;Prangrawee Sangchan;Bhargava Chitti;Caroline A. Thompson;Gerald Henderson;Casey W. Williamson;Jake R. Todd;Divya P. Prajapati;Lucas K. Vitzthum;Andrew B. Sharabi;Jingjing Zou;Assuntina G. Sacco;Charley S. Coffey;Parag Sanghvi;Douglas A. Rahn;Christopher E. Lominska;Colette J. Shen;Bhishamjit S. Chera;Loren K. Mell - 通讯作者:
Loren K. Mell
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
将曲贝替定(T)加入顺铂放化疗(CRT)用于局部晚期宫颈癌和阴道癌:NRG-GY006 这一 III 期随机试验的结果
- DOI:
10.1016/j.ygyno.2025.03.007 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:4.100
- 作者:
Charles A. Leath;Wei Deng;Loren K. Mell;Debra L. Richardson;Joan L. Walker;Laura L. Holman;Jayanthi S. Lea;Sudha R. Amarnath;Luis Javier Santos-Reyes;Rebecca C. Arend;Jyoti Mayadev;Naresh Jegadeesh;Paul DiSilvestro;Hye Sook Chon;Sharad A. Ghamande;Lei Gao;Kevin Albuquerque;Junzo P. Chino;Eric Donnelly;Jonathan M. Feddock;Bradley J. Monk - 通讯作者:
Bradley J. Monk
2974: Generalised Competing Risk models predict relative risk of cancer events in p16+ oropharynx cancer
2974:广义竞争风险模型预测p16+口咽癌中癌症事件的相对风险
- DOI:
10.1016/s0167-8140(24)03070-6 - 发表时间:
2024-05-01 - 期刊:
- 影响因子:5.300
- 作者:
James M. Price;David J. Thomson;Loren K. Mell - 通讯作者:
Loren K. Mell
Loren K. Mell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Loren K. Mell', 18)}}的其他基金
Multi-atlas and whole body radiomics approaches for image-guided treatment of gynecologic cancers
用于妇科癌症图像引导治疗的多图谱和全身放射组学方法
- 批准号:
10641665 - 财政年份:2021
- 资助金额:
$ 25.36万 - 项目类别:
Multi-atlas and whole body radiomics approaches for image-guided treatment of gynecologic cancers
用于妇科癌症图像引导治疗的多图谱和全身放射组学方法
- 批准号:
10361556 - 财政年份:2021
- 资助金额:
$ 25.36万 - 项目类别:
Image-guided bone marrow-sparing IMRT for cervical cancer
图像引导保留骨髓的 IMRT 治疗宫颈癌
- 批准号:
8204379 - 财政年份:2011
- 资助金额:
$ 25.36万 - 项目类别:
相似海外基金
Impact of tissue resident memory T cells on the neuro-immune pathophysiology of anterior eye disease
组织驻留记忆 T 细胞对前眼疾病神经免疫病理生理学的影响
- 批准号:
10556857 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Anterior Insula Projections for Alcohol Drinking/Anxiety Interactions in Female and Male Rats
雌性和雄性大鼠饮酒/焦虑相互作用的前岛叶预测
- 批准号:
10608759 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Fear and anxiety circuit mechanisms in anterior hypothalamic nucleus
下丘脑前核的恐惧和焦虑环路机制
- 批准号:
10789153 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Elucidating signaling networks in Anterior Segment development, repair and diseases
阐明眼前节发育、修复和疾病中的信号网络
- 批准号:
10718122 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
The Intimate Interplay Between Keratoconus, Sex Hormones, and the Anterior Pituitary
圆锥角膜、性激素和垂体前叶之间的密切相互作用
- 批准号:
10746247 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Impact of tissue resident memory T cells on the neuro-immunepathophysiology of anterior eye disease
组织驻留记忆 T 细胞对前眼疾病神经免疫病理生理学的影响
- 批准号:
10804810 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Investigation of the effect of anterior eye shape on myopia progression due to prolonged near work.
研究因长时间近距离工作而导致的前眼形状对近视进展的影响。
- 批准号:
23K09063 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation and characterization of anterior pituitary stem cells from human pluripotent stem cells
人多能干细胞垂体前叶干细胞的产生和表征
- 批准号:
23K08005 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Anterior cruciate ligament injury: towards a gendered environmental approach
前十字韧带损伤:走向性别环境方法
- 批准号:
485090 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Operating Grants
EASI-TOC: Endovascular Acute Stroke Intervention-Tandem OCclusion: atrial of acute cervical internal carotid artery stenting during endovascularthrombectomy for anterior circulation stroke
EASI-TOC:血管内急性卒中干预-串联闭塞:前循环卒中血管内血栓切除术期间急性颈内动脉心房支架置入术
- 批准号:
490056 - 财政年份:2023
- 资助金额:
$ 25.36万 - 项目类别:
Operating Grants